First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Clinical trial NCT05271916 · RECRUITING

Trial details

NCT number: NCT05271916
Sponsor: Shanghai Chest Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer (NSCLC)

Start date: 2022-10-13
Primary completion: 2025-01-01
Enrollment: 140

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.